Immune checkpoint inhibitors may cause specific immune-related reactions, such as pseudo-progression. In particular, malignant pleural effusion tends to worsen due to this phenomenon. However, the appropriate management in such cases is unclear. We report a 73-year-old man with advanced lung adenocarcinoma and malignant pleural effusion who developed pseudo-progression with immune-related interstitial lung disease (irILD) induced by pembrolizumab (Merck & Co., Kenilworth, NJ, USA). After managing them with steroid treatments and chemotherapy, pembrolizumab was re-administered. At the time of writing, 30 months have passed since the re-administration of pembrolizumab without disease progression. This clinical course conveys an appropriate management strategy for patients with pseudo-progression and irILD.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8338124 | PMC |
| http://dx.doi.org/10.7759/cureus.16177 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[F]FDG-PET/CT atypical response patterns to immunotherapy in non-small cell lung cancer patients: long term prognosis assessment and clinical management proposal.
Eur J Nucl Med Mol Imaging
October 2024
Centre Antoine Lacassagne, Nuclear Medicine Department, 33 Avenue de Valombrose, 06100, Nice, France.
Aim: To determine the long-term prognosis of immune-related response profiles (pseudoprogression and dissociated response), not covered by conventional PERCIST criteria, in patients with non-small-cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICPIs).
Methods: 109 patients were prospectively included and underwent [F]FDG-PET/CT at baseline, after 7 weeks (PET1), and 3 months (PET2) of treatment. On PET1, tumor response was assessed using standard PERCIST criteria.
Long‑term control in a patient with lung adenocarcinoma, nonbacterial thrombotic endocarditis and multiple systemic emboli: A case report.
Exp Ther Med
February 2024
Division of Respiratory Medicine, University of Tsukuba Hospital, University of Tsukuba, Tsukuba, Ibaraki 305-8576, Japan.
Systemic emboli are not uncommon in patients with advanced non-small cell lung cancer. The present study describes a rare case of long-term control in a patient with lung adenocarcinoma, nonbacterial thrombotic endocarditis and multiple systemic emboli. Briefly, a 56-year-old man was diagnosed with metastatic lung adenocarcinoma and was treated with pembrolizumab, which was discontinued due to the appearance of a pulmonary immune-related adverse event.
View Article and Find Full Text PDFAssessing Radiological Response to Immunotherapy in Lung Cancer: An Evolving Arena.
Cancer Diagn Progn
January 2024
Wolfson Institute of Population Health, Cancer Research UK Barts Centre, Queen Mary University of London, London, U.K.
In the past decade, immune checkpoint inhibitors (ICIs) have entered the treatment landscape of non-small-cell lung cancer, signalling a paradigm shift within the field characterized by significant survival benefits for patients with advanced and metastatic disease, and especially those with non-targetable genetic oncogenic driver mutations. However, the shift towards immune-based treatments has created new challenges in oncology. Atypical immunotherapy response patterns, including pseudo-progression and hyperprogressive disease, as well as immune-related adverse events have generated the need for new methods to predict patient response to treatment.
View Article and Find Full Text PDFManagement of Non-Melanoma Skin Cancer: Radiologists Challenging and Risk Assessment.
Diagnostics (Basel)
February 2023
Department of Precision Medicine, University of Campania "Luigi Vanvitelli", 80123 Naples, Italy.
Article Synopsis
- Basal cell carcinoma, squamous cell carcinoma, and Merkel cell carcinoma are the primary types of nonmelanoma skin cancers, and their occurrence and mortality rates have increased in recent years, posing challenges for treatment, especially for patients with advanced stages of the disease.
- Improved diagnostic methods that include patient characteristics are essential for better risk assessment, given that those with a history of systemic treatments face higher risks for these cancers.
- The use of PET/CT scans has shown to be more effective than CT and MRI in detecting metastasis, and while immunotherapy has enhanced treatment responses, it also introduces complexities that require radiologists to stay informed on tumor characteristics and potential adverse effects to optimize patient outcomes.
Successful Targeting of CTLA-4 in a Melanoma Clinical Case: A Long-Term "One Stop Therapeutic Shop".
Onco Targets Ther
November 2022
University of Siena, Siena, Italy.
The anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) monoclonal antibody ipilimumab was the first in-class immune-checkpoint inhibitor (ICI) approved for the treatment of melanoma patients. Initially approved for metastatic cutaneous melanoma, treatment with ipilimumab subsequently demonstrated to significantly improve recurrence free survival (RFS) in fully resected, high-risk, stage III melanoma patients. Therapeutic use of ipilimumab has also allowed the initial identification and characterization of unconventional clinical and radiological patterns of response (ie, tumor flare, pseudo-progression) that may occur during ICI therapy, unlike chemotherapy or targeted therapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!